|
2.5 Etiologie - Gènes
|
|
|
|
|
|
|
|
|
To
try to gain a better understanding of the contribution of TP53
mutations in osteosarcoma, study researchers sequenced the TP53 gene in a
random set of 765 osteosarcoma patients, the largest population
evaluated for these mutations to date.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
|
|
|
|
|
Researchers
find those using e-cigarettes daily, especially ones with refillable
tanks, made more effort to give up over a year than infrequent users.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
research -- welcomed by experts in a field marked by a dearth of good
scientific evidence and intense lobbying -- suggests daily use of
so-called "tank" e-cigarettes, designed to be refilled with
nicotine-containing liquids, is most likely to help smokers quit.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
|
|
|
|
Dr.
Offit said it was contradictory that Color was trying to expand testing
to everyone on the same day the two biggest testing companies were
joining forces to try to reduce how often they find these so-called
variants of uncertain significance.
|
|
|
|
|
|
|
|
|
|
|
|
|
Quest
Diagnostics Inc, the world's largest provider of diagnostic testing
services, is working with France's national health agency to build an
expanded database for BRCA1 and BRCA2 gene mutations to better determine
patient hereditary risks of breast and ovarian cancer.
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
|
|
|
|
As
for my fear of overdiagnosis? Wender said it's an issue, but the exact
extent of the problem is unknown. And, he added, much of overdiagnosis
happens in women with ductal carcinoma in situ, which is Stage 0 cancer
that hasn't yet become invasive.
|
|
|
|
|
|
|
|
|
|
|
|
|
The wishy-washy advice is a disservice to women’s health.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
Task Force has posted its draft recommendations and evidence on breast
cancer screening for public comment. The following materials provide an
overview of our process for developing recommendations as well as
details about the new draft recommendations on screening for breast
cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
U.S. Preventive Services Task Force examined clinical studies on
breast-cancer screening, concluding that “some women in their 40s will
benefit from mammography” but that “most will not, while others will be
harmed.”
|
|
|
|
|
|
|
|
|
|
|
|
|
The
new health panel guidelines are based on a review of scientific
evidence showing the benefits of cancer screening outweigh the risk of
overtreatment for women age 50 to 74.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
|
|
|
|
First-of-its-kind
Exploratory Study Investigates Unique Molecular Indicators of Tumors
Associated with Exceptional Treatment Responses to Drug Therapies in
Patients With Cancer
|
|
|
|
|
|
|
|
|
|
|
|
|
Tissue
and clinical data from exceptional responders will be collected at
several sources, including NCI-supported clinical trials, clinical
studies that are actively enrolling at other institutions, and cases
submitted by private practice or community center physicians.
|
|
|
|
|
|
|
|
|
|
|
|
|
Exceptional
responder patients are those who achieved a complete response to a
treatment that would be expected to occur in 10 percent or less of
patients; a partial response to therapy of greater than 6 months that
would be expected in 10 percent or less of patients; or a response at
least three times the duration expected at the beginning of therapy.
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
|
|
With
both PD-1 inhibitors showing one-year overall survival in excess of
70%, compared with less than 40% one-year survival historically, this
battle is turning into a win-win for patients and physicians.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
|
|
|
|
The
partnership covers early-stage treatments that target the enzymes IDO1
and TDO, pathways tumors use to hide from T cells. By inhibiting IDO1
and TDO at the same time, Curadev hopes to unblind the immune system and
prevent tumors from escaping its defenses.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
international Phase III study (EMR 100070-004) is designed to assess
the efficacy and safety of the investigational cancer immunotherapy
avelumab (MSB0010718C), compared with docetaxel, in patients with stage
IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease
progression after receiving a prior platinum-containing doublet therapy.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
companies will collaborate on a Phase 1 study to evaluate the safety
and efficacy of birinapant, TetraLogic’s SMAC-mimetic, in combination
with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients
with relapsed or refractory solid tumors. The study is expected to begin
in late 2015.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
|
|
|
The
new data were not altogether surprising but disappointed investors who
expecting more progress for CAR-T in solid tumors. To date, all of the
excitement surrounding CAR-T has come from very high remission rates in
patients with advanced blood cancers, a smaller commercial market.
|
|
|
|
|
|
